Molecular Biometrics Closes $12.5M Series B Equity Funding
Molecular Biometrics, Inc., a Norwood, MA-based metabolomics company developing novel clinical diagnostic tools for applications in personalized medicine, completed a $12.5 million Series B financing.
New investor Atlas Venture (Waltham, MA) led the round with participation from existing investors Safeguard Scientifics, Inc. (Wayne, PA), and Oxford Bioscience Partners (Boston, MA).
Molecular Biometrics’s proprietary technology is being applied in reproductive health, IVF and neurodegenerative disease (e.g., Parkinson’s disease).
The financing will allow the company to accelerate the global launch of its flagship product, ViaMetrics-E(TM), a non-invasive procedure that is designed to enhance in vitro fertilization (IVF) outcomes, implement manufacturing and product enhancements, and complete its ongoing FDA clinical study.